CLEC4C and systemic lupus erythematosus: In SLE patients with cutaneous involvement, anti-BDCA2 therapy markedly reduces IFN-α and MxA within lesional skin, changes that correlate with improved clinical scores and implicate pDC dominance within the cutaneous niche [218].